For early-stage therapeutic biotech CEO's seeking top-tier yet affordable C-level executive support in fundraising and operations that will stay with you from inception to exit, Collabrity has innovated a leveraged strategic consulting model that is uniquely suited to the needs of our clients. Quality, affordability, and continuity for private therapeutic biotech company CEOs worldwide – I look forward to scheduling a time soon to further explore the exceptional value that Collabrity would bring to your fundraising efforts and operations.Our DNA is from “inside the tent”. We see your challenges from the perspective of CFOs, CBOs, and COOs - and CXO combinations thereof – because those have been our roles. We have spent the bulk of our careers on senior leadership teams as employees of therapeutic biotech companies. Our imprinting experiences were not in consulting, auditing, or investment banking. While our approach may be consultative and our hours less than full-time according to your needs, we can be the corner office partner of CEOs - because our executive suite offices were always a short walk away.Executive quality standards. We come from listed companies, biotech unicorns, and companies backed by top-tier life sciences venture capital firms. We bring to our clients best-in-class analytics, practices, and performance based on executive experience.Yet we are affordable because we are leveraged. As executives, we have spent our careers forming, leading and monitoring G&A and R&D teams to efficiently perform the work of turning transformative research insights into FDA-approved therapies that serve patients. Because of our deep operational experience, we have deconstructed and re-imagined the needs of early-stage biotech CEO’s from scratch and realized that under our guidance we can ensure the bulk of a partnering or financing campaign can be delegated to our highly trained, lower-cost Associates so that we can pass on the economies to our clients.

• 2020-2021 interim CFO consulting engagementso Public microcap company CFO with late-stage oncology therapeutic leader RenovoRxo Lead strategic transactions advisor and interim CFO for late-stage clinical biotech firmo Internal readiness and CEO’s IPO timeline exec for Tenaya Therapeutics (NASDAQ: TNYA)o Implemented key elements of internal control structure for pre-IPO biotecho Writer and editor of Better Therapeutics ((NASDAQ: BTTX) S-4 business sectiono Augmented Coherus (NASDAQ: CHRS) late-stage oncology partnering campaign

Ophthalmic precision medicine firm that developed one of 40 Covid-19 tests authorized by March 2020 for emergency use by the FDA. This PCR-based test is currently commercialized through its CLIA-registered laboratory and serves primarily skilled nursing facilities in California. Founded in 2011, Avellino also has genetic testing operations in Korea, Japan and China and therapeutic R&D programs under development in Northern Ireland.Results:- Raised $5.6M USD in 12 debt financing, Paycheck Protection Program, merchant cash advances and factoring relationships during 5-month pivot to Covid-19 testing in response to the global pandemic.- Created and structured stable revenue model, a consignment sales strategy & billing/collection system enabling insurance reimbursement via revenue cycle management partner.- Initiated strategies, chaired organizational meeting in Seoul, and implemented internal control systems in preparation for prospective KOSDAQ IPO.- Managed hypergrowth of the firm in spite of a legacy of undercapitalization and $5m in payables, which required building inventory rapidly & recruiting key personnel to enlarge the staff by a factor of four.

Provided outsourced FP&A services to immuno-oncology therapeutics leader Bolt Biotherapeutics (NASDAQ:BOLT).

Immuno-oncology biotech harnessing evolutionary power of the immune system to develop adoptive T-cell therapies for cancer.Chief Financial Officer (2018-2019)Vice President, Finance (2017-2018)Results:- Shepherded the company through readiness, achieving 3 confidential regulatory filings with no accounting comments, more than 30 investor meetings, and assembling a bulge-led 4-bookrunner financing syndicate.- Implemented Sarbanes-Oxley policies and ensured regulatory compliance.- Initiated and trained staff members on best practices in budget processes, chaired quarterly audit committee meetings, streamlined GL accounting and reporting within the NetSuite platform, and successfully transitioned accounts payable to an AI-based system.- Forged international Treasury and Cash Management banking relationships as well as key connections with Wall Street analysts.

A leading pure-play, global biosimilar company that develops & commercializes high-quality therapeutics for major regulated markets. Hired as employee 30, company grew to 180 employees. Reporting to CFO, supported successful IPO in November 2014.Vice President, Financial Strategy Provided investor relations, SEC filing, due diligence, valuation, and negotiation support that helped raise net proceeds of more than $500M USD, including Series C, IPO, convertible debt, and public offerings. Chaired C-level business strategy committee, consistently achieving consensus on priorities and action steps involving company financing, M&A, and strategic partnerships. Authored and presented discounted cash flow analyses of more than ten prospective partnering deals as well as quarterly pro forma financial statements, which guided strategic corporate decisions, capital raising, and cash management. Orchestrated rollout and implementation of cloud-based FP&A system to facilitate database-driven cash flow forecasting and budgeting. Successfully defended against hostile-interest takeover, developing the company valuation strategy and taking point as M&A project leader. Facilitated regional licensing of lead internal drug candidate by overseeing due diligence project, which included multi-function redaction and approval of over 100 data room documents and steering 2 on-site visits by prospective international partners that involved 25 internal participants and 5 internal functions. Compiled market research results and conducted financial analyses as chair of product development/steering committee, establishing product portfolio priorities that garnered buy-in/approval from both the Scientific Advisory Board and senior management.

Corporate partnering advisory firm for emergent life science firms (clients in parentheses)• (Proaltus Partners) General partner, co-founder serving small to mid-cap pharma with market research, commercial assessment and asset valuation capabilities.o Launched 8-week Licensing-Out Campaign Solutions™ service module offering expert, comprehensive preparation for clinical stage out-licensing• (Crown Bioscience) Led US West business development as Executive Director o Provided translational oncology research services sales and marketing supporto Drove 50 % annual increase in regional 2012 sales (to $4.5 Mn) o Created dynamic 5-person China-based inside sales lead generation team• (Eureka Therapeutics) Built subcontractor network of 5 partners (India, Brazil, Thailand, Turkey, EU) to license 7-figure biosimilar antibody production cell line solution.

Strategy and new business creation role for contract research services market leader• Led team of 12 Circulating Tumor Cell Center of Excellence alliance major cancer center• Engaged 100+ employees to drive sold-out, marquis American Society Clinical Oncology event

Positioned biomarker development lab for scale-up and growth• Initiated negotiated closed oncology research services deals with 2 major pharmas, exceeding $1.25 Mn revenue target in first 6 months• Managed 3-person business development team

Corporate partnering advisory firm for emergent life science firms (clients in parentheses)• Initiated, negotiated and closed $10 Mn preclinical CNS acquisition of (Adagio Pharma)o Adagio acquirer Cynapsus was acquired by Sunovion in Oct 2016 for $635 Mn• In head of BD role, negotiated and closed a broad, complex 8-figure product partnership with Sanofi-aventis / Genzyme for gene therapy firm (AGTC). Executed in-licenses with MedImmune, U. Alabama• Led oncology communications campaign contributing to $5 Mn Ser A financing (Tau Therapeutics)• Negotiated key terms agreements on 3 product in-license deals. Participated in 2 dozen pitch presentations to top-tier venture capital firms. Developed financial model for investor communications. Specialty pediatric pharma startup (PDxRx)• Delivered analyses and presentations at senior management level:o Business case presented to Eli Lilly management team for proposed (Chorus) spinouto Deal landscape analysis, heart failure gene therapy valuation Enterprise Partners Venture Capital portfolio company (Celladon)o Valuation of GI asset then licensed to P&G Pharma (Aryx )o Board presentation valuing novel CNS therapy (NeurAxon) o Startup business / financing plan for (William Rutter, PhD) Chiron foundero Financial plan for Series D financing (Angiogenix) • Led other business development campaigns:o Phase II obesity candidate Sanderling Ventures portfolio company (Harkness Pharma)o Oncology cell therapy technology platform out-licensing, in-licensing (MaxCyte)o Assessed combinatorial chemistry partnering opportunity (Exelixis) o Delivered ethanol partnering strategy, deal terms (Zymetis)

Under contract with Collabrity Advisors, transaction support practice leader for a boutique consultancy focused on providing corporate partnering and portfolio management expertise to small to mid-sized private and public life science companies.• Progressed to due diligence, key terms discussions with top 5 pharma, contacting 140 potential licencees. Led BD campaign for public Bay Area biotech Nuvelo to partner preclinical Inflammation / Autoimmune platform with > $1 billion peak sales potential• Delivered benchmarking study on 10 deals, critical for data-driven performance assessment of entire corporate BD function Genentech• Prepared, presented “Partner Perspective Value Proposition” Acologix.• Prepared, presented “License Now or Wait” analysis Marcadia.

As a co-founder of PDxRx and under contract with Collabrity Advisors, I led business development efforts for the company. The PDxRx business model consisted of pediatric clinical development and commercialization, with a specific focus on selected pediatric subspecialties: pediatric rheumatologists, nephrologists, endocrinologists, gastroenterologists and acute care specialists. Our mission was to address autoimmune, metabolic and inflammatory diseases in children and adolescents. Our strategy was to acquire assets or rights for promotion in these markets through a direct field sales force dedicated solely to these subspecialties. We sought to become the pediatric market partner of choice for adult-therapeutic focused pharmaceutical and biotechnology companies.

Lead business development responsibility in protein therapeutics, including oncology• Primary author and 5-firm inter-company coordinator of business sections of Advanced Technology Program proposal resulting in 5-year $31 Mn ascorbic acid R&D award.• As lead negotiator closed $10 Mn preclinical oncology alliance Seattle Genetics• As team leader initiated, prepared, submitted National Renewable Energy Laboratory (NREL) proposal resulting in $17 Mn research funding to Genencor over a 3-year period. Supervised team of 20 that included Research Fellows, Vice Presidents, Staff Scientists, Attorneys.• Initiated, negotiated and closed $6.3 Mn chromatography resin licensing deal with BioSepra• Initiated, negotiated and closed $1 Mn complex carbohydrate licensing deal with Cytel• Supervised and trained 7 business development interns• Delivered competitive analysis and co-drafted Form S-1 for IPO of company• Delivered corporate presentations and led partnering discussions at major international conferences: BioAsiaPacific, BioEurope, BioScandanavia and others• Contacted 70+ companies, negotiated 3 license option term sheet agreements for licensing proprietary protein therapeutic re-engineering technology• Negotiated key terms antifungal therapeutic joint venture Manchester Biosciences Incubator • Led aromatics business planning and project management effort that screened 180-plus chemical compound product opportunities and identified quinic acid as lead candidate • Led other business development campaignso rDNA lactoferrin (Agennix)o protein chips (Ciphergen)o computational biology (Xencor)o granulation technology (Rhone-Poulenc)o L-5 sugars (Eastman Fine Chemicals, Pfizer Food Sciences)o polymers (E. I. Dupont de Nemours)o bio-indigo dye (Levi Strauss)o quinic acid (Oregon State University, Optimax)o melanin dye (Biosource Genetics)o functional genomics (Millennium, Incyte)